Welcome to our dedicated page for Labcorp Holdings news (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Labcorp Holdings stock.
Labcorp Holdings Inc (LH) delivers essential clinical diagnostics and advanced laboratory solutions that shape modern medical decision-making. This dedicated news hub provides investors and healthcare professionals with timely updates on Labcorp's operational developments, scientific advancements, and strategic initiatives.
Access curated press releases and analysis covering earnings reports, partnership announcements, and innovations in precision oncology diagnostics. Track Labcorp's progress in genomic sequencing technologies and biopharma collaborations through verified updates from primary sources.
The resource consolidates critical information about Labcorp's laboratory network expansions, regulatory milestones, and service enhancements across clinical testing and drug development sectors. Users gain insights into how the company maintains its leadership through scientific rigor and operational scale.
Bookmark this page for streamlined access to Labcorp's evolving role in healthcare innovation, with updates organized for efficient navigation. Return regularly to stay informed about developments impacting diagnostic capabilities and research partnerships in the life sciences sector.
Labcorp (NYSE: LH) has launched Labcorp Global Trial Connect, a suite of digital solutions to enhance the efficiency of clinical trials. Announced on June 17, 2024, these tools aim to accelerate trial processes at investigator sites by simplifying workflows, improving patient experiences, and aiding biopharma sponsors. Key features include site enablement resources to identify study opportunities and enhance diversity, supply readiness support to prevent delays, and workflow facilitation for better data integration and error reduction. Available to current Labcorp Central Laboratory clients, these solutions promise to speed up study initiation and maintain momentum.
Labcorp announced new strategic service offerings in its precision oncology portfolio on June 3, 2024. These enhancements include 'Labcorp Tissue Complete' and the expansion of the 'OmniSeq INSIGHT' liquid biopsy service. Labcorp Tissue Complete, utilizing the FDA-cleared PGDx elio™ assay, is now available in Geneva and Shanghai to support global clinical trials, aiming to standardize biomarker-directed patient testing. Additionally, OmniSeq INSIGHT now includes circulating tumor DNA (ctDNA) profiling, complementing Labcorp's CGP services by evaluating key biomarkers from blood and tissue specimens. These developments aim to streamline oncology clinical trial access, broaden patient populations, and improve logistical efficiencies.
Labcorp (NYSE: LH) will present multiple abstracts at the 2024 ASCO Annual Meeting from May 31 to June 4 in Chicago, focusing on precision oncology diagnostics for triple-negative breast cancer (TNBC), liquid biopsy, and machine learning for tumor profiling. Key studies include:
1. VEGF-A and immune checkpoint interaction in TNBC, suggesting mechanisms of immune evasion and tumor progression.
2. Novel HLA-Ilo/HLA-IIhi phenotype in TNBC, indicating immune escape markers.
3. A machine learning model for predicting tumor microsatellite instability (MSI) using multi-omics biomarkers.
4. Analytical validation of the Labcorp® Plasma Complete™ test for comprehensive genomic profiling in solid tumors, demonstrating high specificity, accuracy, and sensitivity.
These studies underline Labcorp's commitment to advancing precision oncology and improving patient outcomes through innovative diagnostics and therapeutic strategies.
Labcorp (NYSE: LH), a global leader in laboratory services, will have members of its executive management team present at the 44th Annual William Blair Growth Stock Conference on June 4 at 2:00 p.m. CT. The company aims to discuss its recent innovations and comprehensive service offerings in the lab sector.
Labcorp (NYSE: LH) announced the launch of its first trimester preeclampsia screening test, available for all pregnant individuals between 11 and 14 weeks of gestation to assess the risk of developing preeclampsia before 34 weeks. This test utilizes four early pregnancy biomarkers and boasts a sensitivity of up to 90%, making it more effective than traditional risk assessment methods. Labcorp is now the only laboratory offering preeclampsia risk screening across all pregnancy trimesters in the U.S. This new test builds on Labcorp's previous launches, including an FDA-cleared blood test for severe preeclampsia in later stages of pregnancy.
Labcorp (LH) will be webcasting its Annual Meeting of Shareholders on May 14 at 9:00 a.m. ET. The webcast can be viewed on Labcorp's Investor Relations website, with an archived replay available for one year.
Labcorp (NYSE: LH) has received court approval to acquire assets of Invitae (OTC:NVTAQ), a leading medical genetics company, for $239 million in cash and non-cash consideration. The acquisition will advance Labcorp's specialty testing strategy in areas like oncology and rare diseases. The transaction is expected to enhance patient care, provide insights into health, and support clinical trials and treatment regimens.
Geneoscopy, Inc. announces FDA approval for its noninvasive colorectal cancer screening test, ColoSense, with 93% sensitivity for detecting colorectal cancer and 45% sensitivity for detecting advanced adenomas in average-risk individuals. The breakthrough device provides a dynamic view of disease activity using RNA biomarkers, offering a promising tool for early-age onset CRC detection. The study showed 100% sensitivity for CRC in the 45-49 age group, a critical demographic, with a commercial launch planned in collaboration with Labcorp.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
